Danish debate weighs up medicines access challenges

Lif, the industry organization for Danish and foreign pharmaceutical companies in Denmark, has held a debate to discuss access to new medicines.

Topics considered included whether Danish patients were worse off than patients in countries that Danes normally compare themselves to when it comes to access to new treatments, and whether the Danish Medicines Council - the independent council that completes medicine recommendations and treatment guidelines with medicine recommendations for the five Danish regions - is unnecessarily restrictive.

"Criticism has been raised that the medicines council is unnecessarily restrictive and that it has become difficult to get treatment with new medicine"Also discussed was the worth of the seventh principle for prioritization in the healthcare system regarding individual access to treatment, and the role of real-world data in decision-making.